Notice of NIAID Participation in RFA-HL-26-018, Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
National Institutes of Health (NIH)
About this opportunity
November 22, 2024 - Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed). See NOFO RFA-HL-26-018. National Institute of Allergy and Infectious Diseases (NIAID) This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective for due dates on or after June 18, 2026, in the Notice of Funding Opportunity Announcement (NOFO) RFA-HL-26-018, "Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)l". The following sections of RF...